These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8693644)

  • 1. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
    Kemppainen JA; Wilson EM
    Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
    [No Abstract]   [Full Text] [Related]  

  • 2. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-activator and co-repressor interplay on the human androgen receptor.
    Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
    Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
    Simard J; Singh SM; Labrie F
    Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
    Berrevoets CA; Veldscholte J; Mulder E
    J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
    Karvonen U; Jänne OA; Palvimo JJ
    FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
    Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
    Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casodex: preclinical studies and controversies.
    Furr BJ
    Ann N Y Acad Sci; 1995 Jun; 761():79-96. PubMed ID: 7625752
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative potency of bicalutamide (Casodex) and flutamide (Eulexin).
    Kolvenbag GJ; Furr BJ
    Urology; 1999 Jul; 54(1):194-7. PubMed ID: 10414753
    [No Abstract]   [Full Text] [Related]  

  • 11. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
    Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
    Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
    Furr BJ
    Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
    Maucher A; von Angerer E
    J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
    Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
    Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
    Culig Z; Hobisch A; Hittmair A; Cronauer MV; Radmayr C; Zhang J; Bartsch G; Klocker H
    Prostate; 1997 Jul; 32(2):106-14. PubMed ID: 9215398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of androgen receptor protein is induced by agonist, not by antagonists.
    Furutani T; Watanabe T; Tanimoto K; Hashimoto T; Koutoku H; Kudoh M; Shimizu Y; Kato S; Shikama H
    Biochem Biophys Res Commun; 2002 Jun; 294(4):779-84. PubMed ID: 12061774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
    Freeman SN; Mainwaring WI; Furr BJ
    Br J Cancer; 1989 Nov; 60(5):664-8. PubMed ID: 2803943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.